DeepCyte is a new biotech company that’s using artificial intelligence and single-cell biology to improve drug safety testing. The company recently raised $1.5 million in seed funding to develop its innovative tools. Co-founded by Theodore Alexandrov, Ph.D., and Shawn Owens, DeepCyte aims to help biopharma teams identify not only if a drug is toxic but










